People with the rare growth hormone disorder acromegaly have a significantly higher risk of developing various types of ...

People with the rare growth hormone disorder acromegaly have a significantly higher risk of developing various types of ...

The Palsonify-treated subjects maintained control, with stable growth hormone levels, symptom scores, and pituitary tumour ...

People with the rare growth hormone disorder acromegaly have a significantly higher risk of developing various types of cancer, often at ages younger than typically seen in the general population, ...

Data show that PALSONIFY was well tolerated and IGF-1 levels remained stably controlled during long-term open label ...

Crinetics shares PATHFNDR trial data showing oral Palsonify maintained hormone and symptom control in acromegaly patients ...

Most adults with acromegaly reduced IGF-1 levels and improved acromegaly symptoms with once-monthly subcutaneous octreotide ...

In acromegaly, IGF-I levels are useful for assessing the relative degree of GH excess, because changes in IGF-I correlate with changes in symptoms and soft-tissue growth.

Retail chatter around Crinetics Pharmaceuticals picked up late Sunday after the company released long-term data for its oral ...

Camurus’ Oczyesa receives European marketing authorization for treatment of acromegaly: Lund, Sweden Wednesday, July 2, 2025, 17:00 Hrs [IST] Camurus, an international, science- ...

Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases ...